Showing results (521-530 of 617) with videos related to
Sort By:
Pageof 62
Journal of Neuroinflammation|November 8, 2023
Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injuryEman Soliman, John Leonard, Erwin Kristobal Gudenschwager Basso, et al.Journal of the National Cancer Institute|April 15, 1999
Oral contraceptive use and risk of gestational trophoblastic tumorsJ R Palmer, S G Driscoll, L Rosenberg, et al.Gynecologic Oncology|March 7, 2009
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancerKathleen M Schmeler, Saroj Vadhan-Raj, Pedro T Ramirez, et al.Gynecologic Oncology|October 16, 2022
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trialJohn H Farley, William E Brady, David O'Malley, et al.Gynecologic Oncology|March 22, 2003
beta-catenin nuclear localization is associated with grade in ovarian serous carcinomaChristine M Lee, Hyun Shvartsman, Michael T Deavers, et al.Cancer|February 19, 2010
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarkerAparna A Kamat, Mathew Baldwin, Diana Urbauer, et al.Gynecologic Oncology|December 17, 2003
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 casesBrian M Slomovitz, Thomas W Burke, Patricia J Eifel, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 2, 2017
Ovarian Yolk Sac Tumors; Does Age Matter?Cecile Faure Conter, Caihong Xia, David Gershenson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinomaBrian M Slomovitz, Yunyun Jiang, Melinda S Yates, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 16, 2009
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomasCelestine S Tung, Samuel C Mok, Yvonne T M Tsang, et al.Pageof 62